Synopsis
The use of MRI measures of fatty liver as well as intraabdominal fat will be discussed, particularly as pertain to Nonalcoholic Steatohepatitis and the metabolic syndrome.
The development of MRI-based measures of liver fat (PDFF)
has received great attention in the last 10 years. Although MRS-based measures have been long
been feasible, MRI has the advantages related to whole-liver imaging and greater
distributability. These techniques are
now available from the major MRI vendors and are being offered by a variety of
imaging labs for use in multi-center clinical trials.
Much of the excitement around PDFF measures was motivated
by the rising prevalence of non-alcoholic steatohepatitis (NASH), a metabolic
disease characterized by abnormal triglyceride (fat) deposition in the liver
which leads to liver inflammation, fibrosis, cirrhosis, and ultimately liver
failure and/or liver cancer. It was
hoped that measures of PDFF would be helpful in the diagnosis and
characterization of NASH, and in particular the differentiation between NASH
and non-alcoholic fatty liver (NAFL), a state in which abnormal triglyceride
deposition is present in the liver, but the downstream effects which lead to
morbidity and mortality do not develop.
As drug development for NASH has continued, there is a
growing awareness that NASH may simply represent a particular phenotype of the
metabolic syndrome, which can also manifest with obesity, diabetes mellitus,
coronary artery disease, and peripheral atherosclerosis. Many drugs developed for the treatment of
individual phenotypes have been found to have efficacy against other components
of the metabolic syndrome, for example some drugs designed for control of blood
glucose also can normalize LFTs and lead to reductions in liver fat content.
Some of the focus in fatty liver imaging has shifted
toward imaging changes in metabolism, for example in attempting to assess the
proportions of saturated and unsaturated fatty acids present in hepatic
steatosis, or in measuring location of abdominal fat deposition and relative
proportions of fat and skeletal muscle.
These developments may herald a paradigm shift form imaging isolated
processes to measuring metabolic changes that reflect the overall health of the
patient.
Acknowledgements
No acknowledgement found.References
No reference found.